Breakthrough Mucormycosis Developing on Mucorales-Active Antifungals Portrays a Poor Prognosis in Patients with Hematologic Cancer.
antifungal therapy
breakthrough mold infection
hematologic malignancy
mortality
mucormycosis
Journal
Journal of fungi (Basel, Switzerland)
ISSN: 2309-608X
Titre abrégé: J Fungi (Basel)
Pays: Switzerland
ID NLM: 101671827
Informations de publication
Date de publication:
17 Mar 2021
17 Mar 2021
Historique:
received:
26
02
2021
revised:
12
03
2021
accepted:
15
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Although breakthrough mucormycosis (BT-MCR) is known to develop on mold-active antifungals without Mucorales activity, it can also occur while on Mucorales-active antifungals. Herein, we retrospectively compared the characteristics and outcomes of patients with hematologic malignancies (HMs) or hematopoietic stem cell transplant (HSCT) who developed BT-MCR on mold-active antifungals with or without Mucorales activity. Of the patients developing BT-MCR, 16 were on Mucorales-active antifungals (9 isavuconazole, 6 posaconazole, 1 amphotericin B), and 87 were on other mold-active agents (52 voriconazole, 22 echinocandins, 8 itraconazole, 5 echinocandin + voriconazole). Both groups were largely comparable in clinical characteristics. Patients developing BT-MCR while on Mucorales-active antifungals had higher 42-day mortality, from either symptom onset (63% versus 25%,
Identifiants
pubmed: 33802827
pii: jof7030217
doi: 10.3390/jof7030217
pmc: PMC8002622
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Infect Dis. 2018 Oct 30;67(10):1610-1613
pubmed: 29771293
Antimicrob Agents Chemother. 2019 Oct 22;63(11):
pubmed: 31481441
Antimicrob Agents Chemother. 2019 Jan 29;63(2):
pubmed: 30455245
Expert Rev Mol Diagn. 2018 Oct;18(10):845-854
pubmed: 30203997
Infect Dis Clin North Am. 2016 Mar;30(1):143-63
pubmed: 26897065
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
Clin Infect Dis. 2012 Feb;54 Suppl 1:S79-85
pubmed: 22247450
J Antimicrob Chemother. 2018 Mar 1;73(3):757-763
pubmed: 29194488
Clin Infect Dis. 2006 Jun 1;42(11):1584-91
pubmed: 16652316
J Infect Dis. 2005 Apr 15;191(8):1350-60
pubmed: 15776383
J Infect. 2010 May;60(5):331-7
pubmed: 20138081
Mycoses. 2013 Nov;56(6):638-45
pubmed: 23551865
Clin Infect Dis. 2008 Aug 15;47(4):503-9
pubmed: 18611163
J Infect Dis. 2009 Sep 15;200(6):1002-11
pubmed: 19659439
Clin Microbiol Infect. 2016 Sep;22(9):811.e1-811.e8
pubmed: 27085727
Med Mycol. 2012 Jul;50(5):543-8
pubmed: 22103347
J Infect Dis. 2017 Aug 15;216(suppl_3):S474-S483
pubmed: 28911042
Pharmacotherapy. 2007 Dec;27(12):1644-50
pubmed: 18041885
Mycoses. 2019 Sep;62(9):716-729
pubmed: 31254420
J Antimicrob Chemother. 2012 Sep;67(9):2268-73
pubmed: 22653819
J Infect. 2020 Nov;81(5):802-815
pubmed: 32798532
Blood. 2015 Dec 24;126(26):2790-7
pubmed: 26504183